279 related articles for article (PubMed ID: 31381100)
1. Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury.
Sheikh-Taha M
Am J Health Syst Pharm; 2019 Jan; 76(1):9-12. PubMed ID: 31381100
[TBL] [Abstract][Full Text] [Related]
2. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
[TBL] [Abstract][Full Text] [Related]
3. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
Simon A; Domanovits H; Ay C; Sengoelge G; Levy JH; Spiel AO
J Thromb Haemost; 2017 Jul; 15(7):1317-1321. PubMed ID: 28426914
[TBL] [Abstract][Full Text] [Related]
4. Refractory Dabigatran-Induced Hemorrhage Despite Multiple Idarucizumab Administration and Renal Replacement Therapy.
Flynn F; Richard G; Dobrescu MA; Bouchard J; Williamson D; Brindamour D; Charbonney E; Dupuis S
J Pharm Pract; 2022 Apr; 35(2):302-307. PubMed ID: 32985337
[TBL] [Abstract][Full Text] [Related]
5. Dabigatran Reversal in a Patient With End-Stage Liver Disease and Acute Kidney Injury.
Novak JE; Alamiri K; Yee J
Am J Kidney Dis; 2018 Jan; 71(1):137-141. PubMed ID: 28549534
[TBL] [Abstract][Full Text] [Related]
6. Reversal of Anticoagulation With Dabigatran in an 82-Year-Old Patient With Traumatic Retroperitoneal Arterial Bleeding Using the New Antidote Idarucizumab: A Case Report.
Hofer S; Philipsenburg C; Weigand MA; Brenner T
A A Case Rep; 2016 Dec; 7(11):227-231. PubMed ID: 27669031
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
Sié P
Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
[TBL] [Abstract][Full Text] [Related]
8. Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
Honickel M; Spronk HM; Rossaint R; Stoppe C; van Ryn J; Ten Cate H; Grottke O
Thromb Haemost; 2017 Jun; 117(7):1370-1378. PubMed ID: 28424818
[TBL] [Abstract][Full Text] [Related]
9. Reversal of dabigatran by idarucizumab: when and how?
Vanassche T; Greinacher A; Verhamme P
Expert Rev Hematol; 2016 Jun; 9(6):519-28. PubMed ID: 27166653
[TBL] [Abstract][Full Text] [Related]
10. Reversal of Dabigatran with Idarucizumab.
Sodha NR; Sellke FW
Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):889-93. PubMed ID: 27362456
[TBL] [Abstract][Full Text] [Related]
11. Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience.
Sheikh-Taha M
Am J Cardiovasc Drugs; 2019 Feb; 19(1):59-64. PubMed ID: 30203330
[TBL] [Abstract][Full Text] [Related]
12. Idarucizumab for Dabigatran Reversal.
Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
[TBL] [Abstract][Full Text] [Related]
13. Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
Rosenberg L; Gerstrøm G; Nybo M
Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):407-410. PubMed ID: 27797449
[TBL] [Abstract][Full Text] [Related]
14. Treatment of gastrointestinal bleeding with idarucizumab in a patient receiving dabigatran.
Mourafetis J; Doctor N; Leung S
Am J Health Syst Pharm; 2018 Feb; 75(4):177-182. PubMed ID: 29343478
[TBL] [Abstract][Full Text] [Related]
15. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
[TBL] [Abstract][Full Text] [Related]
16. Idarucizumab (PRAXBIND®) as a sole reversal agent in an unstable hemorrhagic shock patient on an unknown anticoagulant with elevated protime/international normalized ratio (PT/INR).
Kutner S; Scaturo N; Williams B
Am J Emerg Med; 2021 Aug; 46():800.e1-800.e3. PubMed ID: 33612323
[TBL] [Abstract][Full Text] [Related]
17. Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.
Giustozzi M; Verso M; Agnelli G; Becattini C
J Thromb Thrombolysis; 2017 Nov; 44(4):527-535. PubMed ID: 28913672
[TBL] [Abstract][Full Text] [Related]
18. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
[TBL] [Abstract][Full Text] [Related]
19. Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding.
Quintard H; Viard D; Drici MD; Ruetsch C; Samama CM; Ichai C
Thromb Haemost; 2017 Jan; 117(1):196-197. PubMed ID: 27734073
[No Abstract] [Full Text] [Related]
20. Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan.
Fang CW; Tsai YT; Chou PC; Chen HM; Lu CM; Tsao CR; Chen CL; Sun MC; Shih YS; Hsieh CY; Chen LA; Chen PL; Yeh JT; Li YH
J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):815-820. PubMed ID: 30573284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
